Steroid hormone receptors and their clinical significance in cancer

R I Nicholson, R A McClelland, J M W Gee

Introduction

Although all cells within the body are exposed to steroid hormones, their physiological actions are limited to those tissues which contain intracellular binding proteins, termed receptors. These proteins specifically bind the individual classes of steroid hormones with high affinity and transmit the steroid signal to sensitive genes located throughout the chromatin. The type of response subsequently induced is dependent on both the developmental stage and differentiation status of the target tissue, but may involve the control of such diverse end points as cell proliferation, cell death, secretory activity, and cellular mobility. Importantly, the ability of steroid hormones to influence these characteristics is retained in many disease states, notably in certain cancers originating in steroid hormone sensitive tissues including carcinomas of the breast,1 genital tract,2 gastrointestinal tract,3 pancreas,4 lung,5 and also intracranial tumours.6 This has been harnessed therapeutically, with drugs which modify the cellular levels or actions of steroid hormones being commonly used in the treatment of breast, endometrial and prostate cancer.7 These tumours frequently retain steroid hormone receptors and their measurement is currently used diagnostically in several centres to identify potential endocrine responsiveness.

As steroid sensitive cancers are relatively common and as cellular transitions associated with the loss of their hormone sensitivity invariably worsen the prognosis for a patient, considerable effort has been afforded to their study. The examination of steroid hormone receptors is pivotal to our understanding of endocrine sensitivity and therefore the current article attempts to summarise our present knowledge of these proteins specifically in those areas of cancer biology which we hope are of particular interest to the pathologist.

Molecular aspects of steroid hormone receptors

The past decade has seen a remarkable increase in our knowledge of the structure and function of steroid hormone receptors. This has occurred through the isolation and sequence analysis of recombinant DNA clones for the individual receptors. It is now established that the receptor proteins from each of the five classes of steroid hormones, notably oestrogens (ER),7 androgens (AR),7 glucocorticoids (GR),7,12 and mineralocorticoids, as well as the receptors for thyroid hormone,13 1,25-dihydroxy vitamin D3 (VDR),14 retinoids (α, β and γ) and so called “orphan” receptors,10 which do not have recognised physiological ligands as yet (including HNF-4,15 COUP,16 Rev-erb A-alpha,17 Nur77,18 NGFI-B,19 TR3,20 retinoid X receptor,21 P-450 inducers,11 and the DHR3/MHR3 proteins22), show marked conservation of structure and contain various functional domains, including those for ligand and DNA binding.23,24 In each instance the steroid receptors act as ligand inducible nuclear transcription factors, with interactions between activated receptors and hormone response elements (HRE) on the DNA directly modifying gene expression.23-25 Although some differences exist with respect to the organisation and initial cellular localisation of the individual classes of steroid hormone receptors,7,12 they all ultimately act to stimulate or repress mRNA production from sensitive genes, leading to changes in protein synthesis and finally cellular function.23,25 However, it has become increasingly evident that steroid hormone receptors represent only part of the transcriptional apparatus involved in the regulation of responsive genes and that they act in concert with other inducers or suppressors of gene expression.10,26 Thus, hormonally directed genes can show responsiveness to peptide growth factors. This is exemplified by the oestrogen regulated gene pS2 (pNR2) which has been shown to be sensitive to the growth factors transforming growth factor α (TGFα), epidermal growth factor and also insulin-like growth factor 1.25 A further example is seen with PR, traditionally an oestrogen regulated protein, which can also be activated through dopaminergic and adrenergic signalling mechanisms.26 Such interactions raise interesting questions concerning the role of cross-talk between steroid hormone receptors and other signalling pathways in the regulation of transcriptional efficiency, constitutive action of the receptor and acquisition of endocrine resistance. A knowledge of such pathways may provide previously unrecognised opportunities for tumour therapy.10

Methods of detection

The observation that hormone sensitive tissues were able to take up and retain radiolabelled steroids against a concentration gradient of the steroid26 lead to the initial discovery of steroid hormone receptors. This property was subsequently exploited in “test tube” biochemical assays, notably dextran coated charcoal (DCC) adsorption ligand binding assays (LBA)26, generating information on the concentration of...
Steroid hormone receptors within solubilised tissue extracts, together with their binding affinity constants. Unfortunately, the ease of performing these assays and also their subsequent clinical value varies between tumour types and surgical procedures used. Thus, while breast and endometrial cancer samples are relatively accessible enabling valuable data to be readily obtained, it is often essential to remove prostate tumour specimens by transurethral sectioning, a procedure which generates elevated temperatures and consequently is potentially damaging to any receptor proteins.26 Furthermore, the assays are also influenced by both the cellularity of the cancer and the content and associated steroid hormone receptor status of normal or benign tissue. These factors may contribute towards falsely negative or positive receptor results.

More recently developed methodologies rely on direct antigen recognition rather than steroid binding activity, utilising monoclonal antibodies25 specific for the various steroid receptors in both enzyme immunoassays (for example, oestrogen receptor enzyme immunoassay (ER-EIA))26 and also immunocytochemistry (for example, oestrogen receptor immunocytochemical assay (ER-ICA))25. The value of the latter technique lies in its relevance to histological sections and thus the procedure has numerous advantages for the pathologist. Steroid receptors can be directly visualised by a colour reaction within individual cell types. This is not possible using biochemical methods, which require that tissues should be homogenised before being assayed, with an associated loss of information regarding heterogeneity of receptor expression in normal, benign and malignant components of the tumour.26 Immunohistochemical assays can also be applied to biopsied or cytological material1 and thus have the ability to generate accurate results on low cellular tumours. Furthermore, the technique allows several different proteins to be investigated on the multiple sections obtained from each tissue sample, readily permitting the construction of a larger biological profile of the tumour. Scoring of nuclear heterogeneity after immunocytochemical staining is possible either manually or using an image analyzer, both methodologies correlating with each other when carried out by experienced workers.25 Manual assessment involves the construction of a H score27 which takes into account both the percentage positivity and staining intensity, while image analyzers can be used to assess the percentage of nuclear area immunopositivity.32 In breast cancers the use of cut off values32 aids the examination of relations between the degree of ER/PR immunostaining and response to endocrine therapies.34 Intra- and inter-laboratory studies15 monitoring immunocytochemical performance and also external quality assurance (EQA) schemes for steroid hormone receptor immunocytochemistry are finally emerging. The UK Steroid Receptor Quality Assessment Group has recently been established, spearheaded by Dr R Leake (Department of Biochemistry, University of Glasgow), providing new workers with vital information regarding steroid receptor QA materials, QA schemes as well as a reference directory of expert laboratories currently engaged in such assays.

Early immunocytochemical studies using antibodies directed against ER (for example, H222 antibody, available in the ER-ICA kit from Abbott Diagnostics, North Chicago, Illinois, USA) showed that the protein is localised exclusively within the epithelial cell nuclei in suitably fixed cryosections31 (that is, frozen specimens stored at −70°C, sectioned and fixed for 10 to 15 minutes in 3-7% formaldehyde/phosphate buffered saline at room temperature; post-fixed in methanol (five minutes) and acetone (three minutes) at −20°C) of normal and cancerous genital tract, breast, pituitary, and liver. This observation was at odds with the previously held view of this receptor as a cytosolic protein which was subsequently translocated to the nucleus following its activation by oestrogens. It is now believed that, with the exception of glucocorticoid receptors, each class of steroid hormone receptor resides predominantly in the nuclei of steroid sensitive cells.1

Using such antibodies, ER (H222 and 1D5 (Dako, High Wycombe, UK)) and PR may now also be reliably localised in 10% buffered formalin fixed (exposed to formalin for no longer than 24 hours as prolonged fixation results both in decreased receptor immunoreactivity and in the appearance of non-specific cytoplasmic staining), paraffin wax embedded material following the re-exposure of masked antigenic determinants by controlled protease digestion of the tissue sections36 or microwave treatment.37 These procedures maintain excellent tissue preservation, and thus accurate receptor determinations can be made in the invasive component of archival tumours, as well as within small, early cancers which are usually processed entirely as formalin fixed, paraffin wax embedded material.

The cloning of the steroid receptor genes and the generation of specific cDNA and oligonucleotide probes has allowed northern hybridisation analysis to be applied to tumour extracts. However, this procedure, while semi-quantifiable, is subject to many of the problems described for steroid receptor biochemical assays which utilise tumour lysates. Fortunately, several groups have begun to use in situ hybridisation technologies to study hormone receptor mRNA levels in histological sections. Indeed, both isotopic and non-isotopic (notably digoxigenin) probe labelling procedures can now be used successfully to study the cellular expression of steroid receptor mRNA within frozen and paraffin wax embedded tumour material.35 Although in situ hybridisation is often less amenable to routine use than immunohistochemistry, a recent study50 has explored the potential of this technique in understanding defects in the steroid receptor transcription/translation pathway. The exquisite sensitivity of this technique has revealed that more mRNA positive results can be recorded for ER than for the resultant protein,58
implying significant post-transcriptional regulation of ER mRNA, assuming that any negativity recorded for the receptor protein is genuine and not merely the result of poor assay sensitivity.

**Steroid hormone receptor expression in the breast**

Steroid hormones, notably oestrogens, are of central importance in growth regulation of the breast. This requirement is often maintained in the various disease states, including neoplasia. Receptors for the steroid hormones oestrogen and progesterone can thus be demonstrated immunocytochemically in the normal mammary luminal epithelium, but staining is usually sparse (7% of cells) and largely confined to the lobular elements in the premenopausal breast. This is paradoxical as the mammary parenchyma is usually regarded as exquisitely steroid hormone-responsive, suggesting that such ER negativity should perhaps be viewed with caution. It may merely represent the limits of detection of the assay used or may indicate cellular quiescence. ER concentrations in the breast are suppressed at ovulation when there is a surge of oestrogens in premenopausal women so that the ER concentrations are lowest during the luteal phase. This sharply contrasts with PR, which is under regulation by both oestrogen and progesterone and is relatively constant throughout the cycle.

Steroid hormone receptors are largely maintained in benign breast conditions, while elevated expression is often associated with breast neoplasia. Heterogeneity of expression is marked both between patients and within an individual tumour. Approximately 70% of primary breast cancers are ER positive while 50% are PR positive, and the proportion of ER positive tumours increases with age. ER positive tumours are more likely to spread to bone, while ER negative tumours often metastasise to the liver, brain and regional lymph nodes. The measurement of ER and PR concentrations in breast cancer specimens is of therapeutic value, providing a means of preselecting patients for various endocrine treatments (primarily antioestrogens), with approximately 75% of advanced breast cancer patients with tumours positive for ER and PR achieving favourable clinical remission. This compares with only 5–10% of patients with steroid receptor negative disease showing an objective response. Tumours containing higher steroid receptor concentrations are more likely to respond than those with reduced concentrations. PR has been reported to be an independent predictive factor for response to the antioestrogen tamoxifen and the predictability of response may be increased to 90% by measuring in vivo induction of this receptor resultant from the partial agonistic activity shown by tamoxifen acting via an intact ER mechanism. Such receptor assays also provide prognostically useful information. The presence of ER has been correlated with a series of favourable prognostic characteristics, including a well differentiated histology, low nuclear grade, low cellular proliferation, prominent elastosis, slight or absent lymphocytic infiltration, and minimal tumour necrosis. For the first five to 10 years after primary surgery, patients with ER rich tumours have a more favourable prognosis than those with receptor negative disease. Unfortunately, however, with a longer follow up time and in the absence of adjuvant endocrine treatment, the disease free intervals converge. In adjuvant endocrine trials greatest benefit is predictably observed in those women with ER/PR rich cancers.

In the UK the use of these assays to tailor therapy to the tumour characteristics of individual patients is only sparingly applied and a more pragmatic approach is frequently undertaken which uses the relatively non-toxic antioestrogenic drug tamoxifen to assess endocrine responsiveness clinically. This approach has arisen primarily from increases observed in the prediction of clinical response by steroid receptor assessment. An immunohistochemical approach to steroid hormone receptor measurements, however, facilitates the construction of a broader biological view of the tumour and demonstrates that further elements other than steroid receptors can influence and correlate closely with clinical response to endocrine treatments. Thus, the increased expression of various peptide growth factors (notably TGFβ) and their receptors (EGFR and, proto-oncogene products (c-erbB2) and also markers indicative of cell proliferative activity (Ki67) have been associated with loss of endocrine sensitivity despite positivity for steroid receptors often being maintained.

It is also possible that further anomalies could arise in the prediction of clinical response to endocrine therapy using steroid receptor profiles if these receptors were occasionally non-functional. An interesting approach to the identification of functionality of steroid receptors has been to measure their gene products. It is fair to say, however, that the identification of target genes involved in the hormonal control of cell behaviour has lagged behind the analysis of the structure and function of these receptors as transcription factors. Most progress has been made with oestrogen regulated genes, with several groups reporting successful cloning strategies. PR, pS2, pLIV1 and cathepsin D have been described as oestrogen regulated proteins, with all but cathepsin D showing enrichment within ER positive disease. Where studied, the expression of oestrogen regulated gene products in clinical breast cancer, although often associated with endocrine responsiveness and invariably also having prognostic value, does not add substantially to the information gained by ER measurements alone. Where the expression of several oestrogen regulated genes has been studied within the breast cancer population, it is evident that they are not always co-expressed in ER positive disease. Their differential expression may reflect differing biological behaviour patterns of the tumours, with—for
example, ER/pLIV1 dual positivity significantly correlates with lymph node involvement in contrast to ER/pS2 positivity.46

Potentially, the control of such activities may reside in variations in the promoters of individual genes or in the sensitivity of the promoters to mutations in the ER. Possibly the most important value of polymerase chain reaction (PCR) technology in this context is the ability to identify both steroid receptor genes and their mRNA transcribed. Numerous mutations have been identified in human cancers, including breast, endometrium, ovary, cervix, and vulva.2,26,66-68 An expanding number of ER mutations have now been documented, including those which can lead to either a loss of either the hormone or DNA binding domain. Several mutations have been successfully identified, albeit at a low frequency, in human breast cancers in vivo.62,63 These frequently occur through frame shift/termination mutations in the ER gene, generating what has been appropriately described by the group from Texas as “outlaw receptors”64. These mutations may be of some importance in controlling breast cancer growth observed following the acquisition of hormone/antihormone resistance.64 Similarly, mutations in the DNA binding domain could alter the DNA specificity of the receptor leading to promiscuous activation of genes not normally responsive to oestrogens, or result in the loss of DNA binding. Most striking is the recent observation showing that ER variants can interfere with the function of the wild-type receptor,62,64 either by forming inactive heterodimer complexes or by binding to the oestrogen response element (ERE) in a redundant conformation. These observations suggest that mutations can act in a rather insidious way as dominant negative oncoproteins.62

Steroid hormone receptor expression in the female genital tract
The female genital system, like the breast, is a prime target organ for the steroid hormones progesterone and oestrogen. Steroid receptors are present throughout the reproductive tract in the ovaries, endometrium, cervix, and vulva.2 Steroid hormone dependence is particularly marked in the endometrium, which in the premenopausal woman contains glandular epithelial cells (and to a lesser extent stroma) with both ER and PR.2,65 In common with the normal breast, receptors in the endometrium vary noticeably in concentration with the fluctuations that occur in their respective ligands throughout the menstrual cycle.2,65 Thus, ER peaks in the proliferative phase of the cycle when the circulating concentrations of progesterone are low, and subsequently falls under the inhibition of rising progesterone during the secretory phase. PR is induced during the proliferative phase by elevated oestrogen concentrations.

As in the breast, steroid hormone receptors are maintained in the female reproductive tract during the process of neoplasia.2 Similarly, there is a growing recognition that steroid hormone receptors in the genital tumour epithelial cells with diminished tumour differentiation and advancement of malignancy.2,66-68 Thus, in the endometrium, PR (and to a lesser extent ER) concentrations are inversely related to tumour grade and stage, while they are usually diminished in associated metastases.2,26,66-68

Although not of established value as yet, steroid receptor analyses look promising for the stratification of endometrial cancer patients for endocrine therapy (primarily progesterational agents).2,66-68 The sensitivity of these patients to hormone therapy is significant in determining the response rate of 89% for PR positive metastatic endometrial adenocarcinomas compared with only 17% for receptor negative cancers.2,66-68 Unfortunately, the therapeutic usefulness of ER is thought to be more limited.2,26 Indeed, in ovarian cancers the concentrations of ER reported are on average lower than those recorded in breast cancers,66 and this may explain the overall poor and often conflicting objective response rate of ovarian cancer to antioestrogen therapy.

The assessment of steroid receptors is also potentially of important prognostic value in female genital cancers.2 This is most apparent for endometrial cancer, where PR positivity is associated with an increased disease free interval and improved survival.68 The usefulness of ER assessment in genital cancers is again more controversial.2,26,69 although dual assessment of a high tumour ER and PR content is, however, usually an indicator of longer survival.70,71

Steroid hormone receptor expression in the male genital tract
It is known that as with the female, the male reproductive system is also under strict steroid hormone control in both normal and disease states. Thus, the prostate gland contains receptors for androgens (AR) in its secretory epithelia.72 In contrast to the breast, however, there have been difficulties in the development of accurate biochemical and immunocytochemical assays for prostatic AR,69 although research in this field is now expanding rapidly as antibodies to the receptor become more readily available. The steroid receptors ER and PR have also been identified in the prostate.2,65-67 In common with the normal prostate, receptors in the prostate vary noticeably in concentration with the fluctuations that occur in their respective ligands throughout the menstrual cycle.2,65 Thus, ER peaks in the proliferative phase of the cycle when the circulating concentrations of progesterone are low, and subsequently falls under the inhibition of rising progesterone during the secretory phase. PR is induced during the proliferative phase by elevated oestrogen concentrations.
All three of these steroid hormone receptors have been shown to be more apparent in benign prostatic hyperplasia (BPH), while AR concentrations are usually reduced in carcinomas compared with those seen in BPH, with an inverse correlation existing between receptor expression and grade. While the ER and the PR status are of some predictive value in many neoplasms of the female reproductive system and the breast, it is the AR that is of primary importance in prostate carcinoma. Indeed, this forms the rationale for treatment of the disease with antiandrogenic drugs and AR positive tumours usually have a better response to such therapies. Recent data suggest that the scoring of AR immunostaining intensity rather than percentage positivity may possibly discriminate good responders.

As seen with ER in the breast, a number of AR mutations have been detected in clinical prostate cancer specimens and also within the LNCaP prostate carcinoma cell line. Importantly, the AR mutation in LNCaP cells greatly influences the specificity of hormone binding, resulting in receptors that have an increased binding affinity for both oestradiol and progesterone, with the antiandrogen hydroxyflutamide acting as an agonist. Interestingly, Schoenberg et al have identified a mutation in the AR gene in some patients with prostate cancer who also exhibit an agonistic response to flutamide. These data suggest that a knowledge of mutations may be critical in determining appropriate methods of treatment with steroid hormones or antagonists. In clinical material AR mutations are thought to occur as late events and are thus quite prevalent in advanced disease where they have been linked with the acquisition of androgen insensitivity.

Conclusions

It is apparent that steroid hormone receptors are of pivotal importance in the control of growth and development of steroid hormone sensitive tissues in their normal and disease states. This has been harnessed therapeutically, with antihormonal drugs, which bind to these receptors thereby competing with endogenous steroid hormones, frequently being used in the treatment of breast, endometrial and prostatic cancer. The measurement of steroid receptors is now used in many centres to stratify such patients for the potential hormonal/antihormonal responsiveness of their tumours. This is exemplified in breast cancer, where ER and PR are monitored, but is also of growing importance in genital cancers in both women (PR) and men (AR). It is becoming increasingly obvious that a wider knowledge of the molecular and cellular biology of these receptors in their functional and non-functional forms is an essential prerequisite for a full understanding of pathways of steroid hormone sensitivity and insensitivity. Much of this work could be performed by the pathologist, with clinical material representing the final testing ground for experimentally derived hypotheses. It is envisaged that involvement of the pathologist in monitoring steroid hormone receptors would ultimately provide data that might be used to aid in selecting primary or adjuvant therapy, evaluating new therapies, estimating prognosis, and assessing outcome.

steroid hormone receptors and their clinical significance in cancer

895


